Best Cell & Gene Therapy CDMOs in India
· updated as new inspection, certificate, and trial data enters the platform
11
CDMOs tracked
6
Fully scored
3
With FDA records
9
FDA inspections
7
EMA/MHRA GMP certs
6
Warning letters
Cell and gene therapy manufacturing spans two adjacent product classes: living cell products (CAR-T, TCR, NK, stem cell therapies) and the viral vectors used to genetically modify them (AAV, lentiviral, adenoviral). The two are tightly coupled in ex vivo cell engineering — a lentiviral vector CDMO supplies the vector that a cell therapy CDMO uses to modify patient T cells for CAR-T. Sponsors running integrated programs benefit from CDMOs covering both, and the ranking below aggregates that combined view.
For platform-specific rankings, use the dedicated pages: <a href="/modality/cell-therapy">Cell Therapy CDMOs</a>, <a href="/modality/aav">AAV CDMOs</a>, <a href="/modality/lentiviral">Lentiviral Vector CDMOs</a>, <a href="/modality/adenoviral">Adenoviral Vector CDMOs</a>, <a href="/modality/gene-therapy">Gene Therapy CDMOs</a> (vectors only, no cell processing).
FDA inspection outcomes across these CDMOs: 2 NAI (no action), 7 VAI (voluntary action), 0 OAI (official action). Leading inspection & GMP sites: India (5), INDIA (5), United States (4), Ireland (2).
Last updated 2026-08-27. Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
| # | CDMO | Signal Score | Quality | FDA · GMP | Capacity | Programs |
|---|---|---|---|---|---|---|
| 1 |
SG
Syngene International
Bengaluru, India
|
79.7 | 95.9 | 2 insp · 0 GMP | — | 0 programs |
| 2 |
BC
Biocon Biologics
Bangalore, India
|
77.1 | 96.1 | 4 insp · 2 GMP | — | 0 programs |
| 3 |
IP
Intas Pharmaceuticals
Ahmedabad, India
|
76.8 | 100.0 | 0 insp · 5 GMP | — | 0 programs |
| 4 |
GZ
Genezen
Indianapolis, IN · Lexington, MA
|
70.7 | 84.1 | 3 insp · 0 GMP | Available | 0 programs |
| 5 |
IU
Indiana University Vector Production Facility
Indianapolis, IN
|
66.2 | — | — | — | 49 programs |
| 6 |
SS
Singota Solutions
Bloomington, IN
|
59.0 | — | — | — | 0 programs |
| — |
Kemwell Biopharma
Bengaluru, India
|
Profiled | — | — | — | 0 programs |
| — |
Kemwell Biopharma, Bangalore
Bengaluru, India
|
Profiled | — | — | — | 0 programs |
| — |
Laurus Labs
Hyderabad, India
|
Profiled | — | — | — | 0 programs |
| — |
Kodo LifeScience Pvt. Ltd.
Valsad, Gujarat, India
|
Profiled | — | — | — | 0 programs |
| — |
Kodo Lifescience Private Limited
Vapi/Valsad, India
|
Profiled | — | — | — | 0 programs |
What to evaluate in a Cell & Gene Therapy CDMO
Integrated vs point-solution CDMO
Ex vivo cell therapy programs benefit from CDMOs handling both vector and cell processing under one roof. Point-solution CDMOs specialize deeper but add tech-transfer complexity.
Regulatory record by process class
Cell therapy and viral vector inspections are separately scoped. Verify the CDMO's inspection record on the specific process class your program will use.
Chain-of-identity + cold chain
Autologous cell therapy demands per-patient scheduling, batch-of-one tracking, and cold-chain logistics that CDMOs vary meaningfully on. Confirm the CDMO's chain-of-identity software and cryopreservation posture.
Commercial track record
For late-stage programs, CDMOs with commercial-approved cell or gene therapy products on file carry demonstrable posture that ranking algorithms only partially capture.
How do Indian CDMOs compare to Chinese and Korean alternatives on regulatory posture?
Indian CDMOs have historically led Asian peers in FDA inspection density — the FDA maintains a large inspection presence in India and Indian pharmaceutical exports to the US are among the highest globally. That translates to Indian CDMOs typically holding more FDA inspections on record than Chinese or Korean counterparts of comparable size. That said, inspection density is not the same as inspection outcome — the Signal Score's Quality Compliance pillar weights the classification (NAI/VAI/OAI), not just the count. Sponsors comparing Asian CDMOs should focus on the specific facility's inspection outcome record, not the country-aggregate; individual profile pages surface facility-level detail.
Which Indian CDMOs handle biologics and advanced therapy modalities?
India's CDMO base has traditionally been strongest in small molecules and oral solid dosage forms, but the biologics and advanced-therapy footprint has grown substantially. Notable capabilities exist across mAb manufacturing, biosimilar production, and increasingly viral vector + cell therapy. Cross-reference with modality pages to filter Indian CDMOs by capability class: biologics, mRNA, cell therapy, or the gene therapy umbrella. Individual CDMO profile pages surface the specific modality capabilities on file.
US and EU regulatory considerations for India-manufactured drug supply
Indian CDMOs supplying US markets need active FDA registrations and pre-approval inspection posture; the FDA has been publicly focused on Indian generic pharmaceutical quality for years, and inspection outcomes there materially affect commercial supply eligibility. EU supply requires EMA GMP certification with an EU-based Qualified Person for batch release, which for Indian-manufactured material requires either an EU-based CDMO partner for release or an in-house EU QP arrangement. The Signal Score's Quality Compliance pillar captures FDA + EMA + MHRA data directly, so Indian CDMOs with cross-jurisdictional posture rank higher on this pillar than domestic-market-only competitors.
Cell & Gene Therapy CDMOs — Frequently Asked Questions
Who are the top Cell & Gene Therapy CDMOs?
By CDMO Signal's independent Signal Score, the top-ranked Cell & Gene Therapy CDMOs include Syngene International, Biocon Biologics, Intas Pharmaceuticals. See the full ranked table above — scored on FDA, clinical, financial, and capacity data.
How many Cell & Gene Therapy CDMOs have FDA inspection records?
CDMO Signal tracks 3 Cell & Gene Therapy CDMOs with FDA inspection records and 7 EMA/MHRA GMP certificates across the group.
What should I look for in a cell and gene therapy CDMO?
Start with process class match — cell therapy vs vector vs both. For ex vivo programs benefit from integrated CDMOs. Verify inspection record on the specific process class, confirm capacity match to your patient volume, and prioritize CDMOs with commercial-scale posture for late-stage work.
How many cell and gene therapy CDMOs does CDMO Signal track?
109 CDMOs are tracked as cell or gene therapy manufacturers — the union of cell therapy, AAV, lentiviral, adenoviral, and gene therapy-tagged CDMOs. This is the broadest advanced-therapy candidate list on our platform.
Related modalities